09 Feb 2026
Rethinking Capital – Alternative funding models for biotech
Biotech funding is evolving. Explore alternative capital models, structured liquidity and new investor types shaping how emerging companies fund innovation.
Related Videos
-
How clinical data strategy shapes CGT success. Miguel Forte explores the role of geography, operations and trial design in generating meaningful data. -
CGT investment is expanding beyond therapeutics. Explore why investors are backing the tools, platforms and technologies powering the industry. -
What makes a biotech company fundable in 2026? Leading investors reveal the science, data, manufacturing and strategy milestones that drive funding decisions. -
The Investment Summit opens with Christiaan Engstrom, Founder of BLPN, sharing perspectives on capital, strategy and the evolving future of advanced therapies investment.